Ratings Novo Nordisk A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 18/09/2024 pm IST			5-day change	1st Jan Change
882.20 ^DKK	-2.35%		-0.93%	+26.37%

18/09	Hims & Hers offers compounded Wegovy for $99 a month to select professions	RE
18/09	NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
According to Refinitiv, the company's ESG score for its industry is good.

The prospective high growth for the next fiscal years is among the main assets of the company
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
The group usually releases upbeat results with huge surprise rates.

With an expected P/E ratio at 39.78 and 31.27 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Source: Surperformance

Source: Refinitiv

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	NOVO NORDISK A/S				60TCr
	ELI LILLY AND COMPANY				82TCr
	JOHNSON & JOHNSON				40TCr
	ABBVIE INC.				34TCr
	MERCK & CO., INC.				30TCr
	ROCHE HOLDING AG				25TCr
	ASTRAZENECA PLC				24TCr
	NOVARTIS AG				23TCr
	AMGEN INC.				18TCr
	PFIZER, INC.				17TCr
	Average				35.36TCr
	Weighted average by Cap.